Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Highlights from the San Antonio Breast Cancer.

Highlights in the management of breast cancer How to improve the outcome of Triple-Negative Breast Cancer Claudia Bighin IRCSS – AOU S. Martino – IST Genova.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.

Presented By Raymond Huang at 2014 ASCO Annual Meeting

The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Role of MRI in Breast Cancer Angela Kong Princess Margaret Hospital.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Gunter von Minckwitz, MD, PhD Chairman of German Breast Group Germany

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

The Role of Ultrasound of the Regional Nodal Basins in Staging Patients with Triple Negative Breast Cancer: Implications for Local-Regional Treatment Simona.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Pritchard KI et al. Proc SABCS 2010;Abstract P

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

Gerber, B; Marx, M; Untch, M; Faridi, A Breast Reconstruction Following Cancer Treatment Dtsch Arztebl Int 2015; 112(35-36): ; DOI: /arztebl

Can PET/CT and PET FDG predict Chemotherapy response in lung cancer patients? By: Megan Broscious.

The Effect on pCR of Bevacizumab and/or Antimetabolites Added to Standard Neoadjuvant Chemotherapy: NSABP Protocol B-40 1 Neoadjuvant Bevacizumab and Anthracycline–Taxane-Based.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.

Presented By Michael Overman at 2016 ASCO Annual Meeting

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Neoadjuvant Therapy for Triple Negative Breast Cancer

Volume 389, Issue 10087, Pages (June 2017)

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

Adjuvant Therapy of Triple Negative Breast Cancer

Az Ospedaliero Universitaria di Ferrara

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

CCO Independent Conference Coverage

Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC CCO Independent Conference Highlights*

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Perspectives on Triple-Negative Breast Cancer

BRCA, HRR Deficiency, and PARP Inhibitors

سرطان الثدي Breast Cancer

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Counseling Patients About Germline BRCA Mutations

Managing gBRCA-Positive Metastatic Breast Cancer

Untch M et al. Proc SABCS 2010;Abstract P

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Volume 64, Issue 3, Pages (September 2013)

Presented By Praful Ravi at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Hormone Receptor-Positive Advanced Breast Cancer Introduction

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Preparing for Checkpoint Inhibitors in Breast Cancer

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Clinical Focus.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional.

Prevalence of gBRCA1/2 mutations stratified by (A) FIGO stage, and (B) family history of cancer. Prevalence of gBRCA1/2 mutations stratified by (A) FIGO.

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC) – Results from GeparSixto Gunter von Minckwitz, Eric Hahnen, Peter A. Fasching, Jan Hauke, Andreas Schneeweiss, Christoph T. Salat, Mahdi Rezai, Jens U. Blohmer, Dirk M. Zahm, Christian Jackisch, Bernd Gerber, Peter Klare, Sherko Kümmel, Holger Eidtmann, Stephan Paepke, Valentina Nekljudova, Sibylle Loibl, Michael Untch, Rita Schmutzler for the GBG/AGO-B study groups Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Introduction Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 3 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 4 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Selected Objectives Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Key Eligibility Criteria Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR Rates (ypT0 ypN0) Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 8 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Characteristics of patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR Rates (%) in Patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 11 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR (ypT0 ypN0) in all Patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR (ypT0/is ypN0) in all Patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Prediction of Carboplatin Effect on pCR Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Summary Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Conclusion Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Acknowledgements Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting